DOCSLIB.ORG

Guidelines for Diagnosis, Treatment and Prevention of Visceral Leishmaniasis in Somalia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guidelines for Diagnosis, Treatment and Prevention of Visceral Leishmaniasis in Somalia Somali Federal Government Ministry of Health Guidelines for diagnosis, treatment and prevention of visceral leishmaniasis in Somalia 2012 Contents Acronyms ...................................................................................................................... 4 Acknowledgements ............................................................................................................ 5 1. Introduction .............................................................................................................. 7 1.1 Background information ............................................................................................................. 7 1.2 Life-cycle and transmission patterns .......................................................................................... 8 1.3 Human infection and disease ..................................................................................................... 8 2. Diagnosis ................................................................................................................. 9 2.1 Clinical diagnosis ........................................................................................................................ 9 2.2 Laboratorydiagnosis ................................................................................................................. 10 2.3 Diagnosis of primary kala-azar ................................................................................................ 13 2.4 Diagnosis of relapse ................................................................................................................ 15 2.5 Diagnosis of PKDL ................................................................................................................... 15 3. Treatment .............................................................................................................. 15 3.1 Treatment of primary kala-azar (new cases) ........................................................................... 15 3.2 Treatment of relapse of kala-azar ............................................................................................ 18 3.3. Treatment of PKDL .................................................................................................................. 19 3.4 Other treatment related issues and special situations ............................................................ 20 3.5. Treatment of concurrent infection and malnutrition ................................................................. 22 4. Information system ................................................................................................... 32 5. Prevention and control .............................................................................................. 32 6. Annexes ................................................................................................................ 33 Annex 1. rK39 rapid diagnostic test procedure ....................................................................................... 33 Annex 3. Lymph node aspirate procedure ............................................................................. 42 Annex 4. Bone marrow aspiration procedures ........................................................................ 43 Annex 5. Procedures for splenic aspiration ............................................................................ 45 Annex 6. Preparation and examination of aspirates. Grading of parasites ..................................... 47 Annex 7. Kala-azar laboratory register book (left page) ............................................................ 51 Annex 8. Kala-azar treatment register book (left page) ............................................................. 53 Annex 9. Kala-azar patient treatment card (front) .................................................................... 55 Annex 10. Kala-azar patient discharge card ........................................................................... 57 Annex 11. Dosage and precautions for the use of sodium stibogluconate (SSG) ............................ 58 Annex 12. Dosage and precautions for the use of paromomycin (aminosidine). .................................... 60 Annex 13. Dosage, administration and precautions for meglumine antimoniate. .................................... 62 Annex 14. Anthropometry and nutrition therapy look-up tables. .............................................................. 64 Annex 15. Overview of treatment for concurrent illnesses in kala-azar. .................................................. 73 Annex 16. Drug guidelines for kala-azar .................................................................................................. 75 Annex 17. Kala-azar monthly reporting forms.......................................................................................... 76 Annex 18. Kala-azar weekly reporting forms .......................................................................... 81 Annex 19. Kala-azar line listing file (to be sent to central database on regular basis) ....................... 82 Acronyms DAT Direct agglutination test FDA Freeze – dried antigen IM Intramuscular IV Intravenous KA Kala-azar ME Mercapto-ethanol ORS Oral rehydration salt PKDL Post kala-azar dermal leishmaniasis RBC Red blood cells RDT Rapid diagnostic test RR Respiratory rate SSG Sodium stibogluconate TFC Therapeutic feeding centre TOC Test of cure VL Visceral leishmaniasis WBC White blood cells WHO World Health Organization Acknowledgements The Visceral Leishmaniasis (VL) guideline for Somalia has been updated through a highly participatory process involving officials from the Ministry of Health, Non-governmental Organizations supporting the various endemic kala-azar treatment centres, World Health Organization representatives from Somalia and EMRO, and national partners. I sincerely appreciate and commend the role of the World Health Organization in supporting the Ministry of Health technically and logistically without which this document would have not been materialized. I would like to thank health workers in kala-azar treatment facilities and the various INGOs supporting those facilities. I am fully cognizant that without their commitments and continuous daily efforts in diagnosing, treating and monitoring patients, no progress on kala- azar guidelines would have been possible. A special thank you is extended to Dr Marthe Everard, WR for Somalia, for her support, to Dr José Postigo of WHO EMRO, and Dr Mohamed M Fuje and Godela von Döhren of WHO Somalia for valuable comments, guidance and effective assistance during the guidelines preparation and printing process. The guidance provided in this document has been drawn from vast experience and lessons learnt from global, regional and local level. We hope the guideline will standardize and unify kala-azar management in the endemic regions and will be able to significantly reduce the high burden of kala-azar in the endemic states. Mr. Duale Adam Mohamed Director General Ministry of Health, TFG Somalia Mogadishu 23rd July, 2012. Guidelines for diagnosis, treatment and prevention of visceral leishmaniasis in Somalia 1. Introduction 1.1 Background information Leishmaniases are caused by over 20 species of parasitic protozoa of the genus Leishmania. The disease, transmitted to humans by sandflies (Phlebotomus and Lutzomyia species), is endemic in 98 countries or territories, affecting around two million people each year. Depending on the species of the parasite and the immune response of the host the disease spectrum of leishmaniasis ranges from self-healing skin lesions to a fatal systemic disease called visceral leishmaniasis (VL) which is also known as kala-azar (KA), a Hindi term meaning ‘black fever’. Human leishmanial infections can result in 3 main forms of disease: Cutaneous leishmaniasis Muco-cutaneous leishmaniasis Visceral leishmaniasis (kala-azar) Visceral leishmaniasis (kala-azar) is a deadly disease caused by the protozoan Leishmania parasite, transmitted through the bite of Phlebotomus sandflies. The World Health Organization (WHO) estimates that globally about 500,000 new cases and over 50,000 deaths of kala-azar occur every year, over 90 % of these cases are from six countries: Bangladesh, Brazil, Ethiopia, India, Nepal and the Sudan. In Africa, there are five countries endemic for VL, namely Ethiopia, Kenya, Somalia, Uganda and the Sudan. Kala- azar generally affects poor and neglected populations living in remote rural areas. If not treated more than 95% of kala-azar cases will eventually die. Eastern Africa is one of the world’s main kala-azar endemic areas, with the majority of the burden being concentrated in focal areas in the east and south-east of Sudan. In Somalia, kala-azar is caused by Leishmania donovani. Phlebotomus martinii is the predominant vector in Somalia, but also P. vansomerenae was reported as possible vector (Trans R Soc Trop Med Hyg. 2003 Nov–Dec;97(6):667–71) . Man is believed to be the only reservoir and transmission is believed to be anthroponotic. Anecdotal cases were described as early as 1935, but VL was first officially reported in 1943, with the first outbreak reported in 1952 from Daarbuluk, Hargeisa. An endemic focus was described in 1965, with 12 cases diagnosed in Middle Shabele region, the majority of which occurred in young age groups and originated from the province capital Jowhar. Further VL cases were reported in 1995‐6 from the Lower Juba region by MSF‐B (Belgian Section) and a case was identified
Load more

Recommended publications
  • Vectorborne Transmission of Leishmania Infantum from Hounds, United States
    Vectorborne Transmission of Leishmania infantum from Hounds, United States Robert G. Schaut, Maricela Robles-Murguia, and Missouri (total range 21 states) (12). During 2010–2013, Rachel Juelsgaard, Kevin J. Esch, we assessed whether L. infantum circulating among hunting Lyric C. Bartholomay, Marcelo Ramalho-Ortigao, dogs in the United States can fully develop within sandflies Christine A. Petersen and be transmitted to a susceptible vertebrate host. Leishmaniasis is a zoonotic disease caused by predomi- The Study nantly vectorborne Leishmania spp. In the United States, A total of 300 laboratory-reared female Lu. longipalpis canine visceral leishmaniasis is common among hounds, sandflies were allowed to feed on 2 hounds naturally in- and L. infantum vertical transmission among hounds has been confirmed. We found thatL. infantum from hounds re- fected with L. infantum, strain MCAN/US/2001/FOXY- mains infective in sandflies, underscoring the risk for human MO1 or a closely related strain. During 2007–2011, the exposure by vectorborne transmission. hounds had been tested for infection with Leishmania spp. by ELISA, PCR, and Dual Path Platform Test (Chembio Diagnostic Systems, Inc. Medford, NY, USA (Table 1). L. eishmaniasis is endemic to 98 countries (1). Canids are infantum development in these sandflies was assessed by Lthe reservoir for zoonotic human visceral leishmani- dissecting flies starting at 72 hours after feeding and every asis (VL) (2), and canine VL was detected in the United other day thereafter. Migration and attachment of parasites States in 1980 (3). Subsequent investigation demonstrated to the stomodeal valve of the sandfly and formation of a that many US hounds were infected with Leishmania infan- gel-like plug were evident at 10 days after feeding (Figure tum (4).
    [Show full text]
  • Regulatory Mechanisms of Leishmania Aquaglyceroporin AQP1 Mansi Sharma Florida International University, [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 11-6-2015 Regulatory mechanisms of Leishmania Aquaglyceroporin AQP1 Mansi Sharma Florida International University, [email protected] DOI: 10.25148/etd.FIDC000197 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Parasitology Commons Recommended Citation Sharma, Mansi, "Regulatory mechanisms of Leishmania Aquaglyceroporin AQP1" (2015). FIU Electronic Theses and Dissertations. 2300. https://digitalcommons.fiu.edu/etd/2300 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida REGULATORY MECHANISMS OF LEISHMANIA AQUAGLYCEROPORIN AQP1 A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in BIOLOGY by Mansi Sharma 2015 To: Dean Michael R. Heithaus College of Arts and Sciences This dissertation, written by Mansi Sharma, and entitled, Regulatory Mechanisms of Leishmania Aquaglyceroporin AQP1, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Lidia Kos _____________________________________ Kathleen
    [Show full text]
  • Visceral Leishmaniasis (Kala-Azar) and Malaria Coinfection in an Immigrant in the State of Terengganu, Malaysia: a Case Report
    Journal of Microbiology, Immunology and Infection (2011) 44,72e76 available at www.sciencedirect.com journal homepage: www.e-jmii.com CASE REPORT Visceral leishmaniasis (kala-azar) and malaria coinfection in an immigrant in the state of Terengganu, Malaysia: A case report Ahmad Kashfi Ab Rahman a,*, Fatimah Haslina Abdullah b a Infectious Disease Clinic, Department of Medicine, Hospital Sultanah Nur Zahirah, Jalan Sultan Mahmud, 20400 Kuala Terengganu, Malaysia b Microbiology Unit, Department of Pathology, Hospital Sultanah Nur Zahirah, Jalan Sultan Mahmud, 20400 Kuala Terengganu, Malaysia Received 28 April 2009; received in revised form 30 July 2009; accepted 30 November 2009 KEYWORDS Malaria is endemic in Malaysia. Leishmaniasis is a protozoan infection rarely reported in Amphotericin B; Malaysia. Here, a 24-year-old Nepalese man who presented with prolonged fever and he- Coinfection; patosplenomegaly is reported. Blood film examination confirmed a Plasmodium vivax ma- Leishmaniasis; laria infection. Despite being adequately treated for malaria, his fever persisted. Bone Malaria; marrow examination showed presence of Leishman-Donovan complex. He was success- Treatment fully treated with prolonged course of amphotericin B. The case highlights the impor- tance of awareness among the treating physicians of this disease occurring in a foreign national from an endemic region when he presents with fever and hepatosplenomegaly. Coinfection with malaria can occur although it is rare. It can cause significant delay of the diagnosis of leishmaniasis. Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved. Introduction leishmaniasis is not. Malaysia is considered free of endemic Leishmania species although few species of Malaysian sandflies have been described, possibly because the sand- Malaysia is a tropical country and located in the region of 1,3 Southeast Asia.
    [Show full text]
  • History of Kala-Azar Is Older Than the Dated Records
    Professor C. P. Thakur, MD, FRCP (London & Edin.) Emeritus Professor of Medicine, Patna Medical College Member of Parliament, Former Union Minister of Health, Government of India Chairman, Balaji Utthan Sansthan, Uma Complex, Fraser Road – Patna-800 001, Bihar. Tel.: +91-0612-2221797, Fax:+91-0612-2239423 Email: [email protected], [email protected], [email protected] Website: www.bus.org.in “History of kala-azar is older than the dated records. In those days malaria was very common and some epidemics of kala-azar were passed as toxic malaria. Twining writing in 1835 described a condition that he called “endemic cachexia of the tropical counties that are subject to paludal exhalations”. The disease remained unrecognized for a faily long time but the searching nature of human mind could come to a final diagnosis, though many aspects of the disease are still unexplored” • Leishmaniasis Cachexial Fever • Internal Catechetic fever leishmaniasis Dum-Dum Fever • Visceral Burdwan Fever leishmaniasis Sirkari Disease • General Sahib’s disease leishmaniasis Kala-dukh • Kala-azar of Kala-jwar adults Kala-hazar • Indian kala-azar Assam fever • Black Fever Leishman-Donovan Disease • Black Sickness Infantile Kala-azar (Nicolle) • Tropical leishmaniasis Infantile leishmaniasis • Tropical cachexia Mediterranean Kala-azar • Tropical Kala-azar Mediterranean leishmaniasis • Tropical Febrile splenic Anaemia (Fede) Splenomegaly Anaemia infantum a leishmania • Non-malarial (Pianese) remittent fever Leishmania anaemia (Jemme • Malaria Cachexia (in error)
    [Show full text]
  • Leishmaniasis Gap Analysis Report and Action Plan
    30 December 2015 Leishmaniasis Gap Analysis Report and Action Plan Strengthening the Epidemiologial Surveillance, Diagnosis and Treatment of Visceral and Cutaneous Leishmaniasis in Albania, Jordan and Pakistan Connecting Organisations for Regional Disease Key Contributors: Surveillance (CORDS) Immeuble le Bonnel 20, Rue de la Villette 69328 LYON Dr Syed M. Mursalin EDEX 03, FRANCE Dr Sami Adel Sheikh Ali Tel. +33 (0)4 26 68 50 14 Email: [email protected] Dr James Crilly SIRET No 78948176900014 Dr Silvia Bino Published 30 December 2015 Editor: Ashley M. Bersani MPH, CPH List of Acronyms ACL Anthroponotic Cutaneous Leishmaniasis AIDS Acquired Immunodeficiency Syndrome CanL Canine Leishmaniasis CL Cutaneous Leishmaniasis CORDS Connecting Organisations for Regional Disease Surveillance DALY Disability-Adjusted Life Year DNDi Drugs for Neglected Diseases initiative IMC International Medical Corps IRC International Rescue Committee LHW Lady Health Worker MECIDS Middle East Consortium on Infectious Disease Surveillance ML Mucocutaneous Leishmaniasis MoA Ministry of Agriculture MoE Ministry of Education MoH Ministry of Health MoT Ministry of Tourism MSF Médecins Sans Frontières/Doctors Without Borders ND Neglected Disease NGO Non-governmental Organisation NTD Neglected Tropical Disease PCR Polymerase Chain Reaction PKDL Post Kala-Azar Dermal Leishmaniasis POHA Pak (Pakistan) One Health Alliance PZDD Parasitic and Zoonotic Diseases Department RDT Rapid Diagnostic Test SECID Southeast European Centre for Surveillance and Control of Infectious
    [Show full text]
  • Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity
    microorganisms Review Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity John M. Curtin 1,2,* and Naomi E. Aronson 2 1 Infectious Diseases Service, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA 2 Infectious Diseases Division, Uniformed Services University, Bethesda, MD 20814, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-011-301-295-6400 Abstract: Leishmaniasis, a chronic and persistent intracellular protozoal infection caused by many different species within the genus Leishmania, is an unfamiliar disease to most North American providers. Clinical presentations may include asymptomatic and symptomatic visceral leishmaniasis (so-called Kala-azar), as well as cutaneous or mucosal disease. Although cutaneous leishmaniasis (caused by Leishmania mexicana in the United States) is endemic in some southwest states, other causes for concern include reactivation of imported visceral leishmaniasis remotely in time from the initial infection, and the possible long-term complications of chronic inflammation from asymptomatic infection. Climate change, the identification of competent vectors and reservoirs, a highly mobile populace, significant population groups with proven exposure history, HIV, and widespread use of immunosuppressive medications and organ transplant all create the potential for increased frequency of leishmaniasis in the U.S. Together, these factors could contribute to leishmaniasis emerging as a health threat in the U.S., including the possibility of sustained autochthonous spread of newly introduced visceral disease. We summarize recent data examining the epidemiology and major risk factors for acquisition of cutaneous and visceral leishmaniasis, with a special focus on Citation: Curtin, J.M.; Aronson, N.E.
    [Show full text]
  • Drugs for Amebiais, Giardiasis, Trichomoniasis & Leishmaniasis
    Antiprotozoal drugs Drugs for amebiasis, giardiasis, trichomoniasis & leishmaniasis Edited by: H. Mirkhani, Pharm D, Ph D Dept. Pharmacology Shiraz University of Medical Sciences Contents Amebiasis, giardiasis and trichomoniasis ........................................................................................................... 2 Metronidazole ..................................................................................................................................................... 2 Iodoquinol ........................................................................................................................................................... 2 Paromomycin ...................................................................................................................................................... 3 Mechanism of Action ...................................................................................................................................... 3 Antimicrobial effects; therapeutics uses ......................................................................................................... 3 Leishmaniasis ...................................................................................................................................................... 4 Antimonial agents ............................................................................................................................................... 5 Mechanism of action and drug resistance ......................................................................................................
    [Show full text]
  • Visceral Leishmaniasis: a Global Overview
    J Glob Health Sci. 2020 Jun;2(1):e3 https://doi.org/10.35500/jghs.2020.2.e3 pISSN 2671-6925·eISSN 2671-6933 Review Article Visceral leishmaniasis: a global overview Richard G. Wamai ,1 Jorja Kahn ,2 Jamie McGloin ,3 Galen Ziaggi 3 1Department of Cultures, Societies and Global Studies, Northeastern University, College of Social Sciences and Humanities, Integrated Initiative for Global Health, Boston, MA, USA 2Department of Behavioral Neuroscience, Northeastern University, College of Science, Boston, MA, USA 3Department of Health Sciences, Northeastern University, Bouvé College of Health Science, Boston, MA, USA Received: Feb 1, 2020 ABSTRACT Accepted: Mar 14, 2020 Correspondence to The leishmaniases are protozoan infections that are among the neglected tropical diseases Richard G. Wamai (NTDs). Over one billion people are at risk of these diseases in virtually all continents. Department of Cultures, Societies and Global These diseases debilitate large numbers of people, keeping them from full, productive lives. Studies, Northeastern University, College of Visceral leishmaniasis (VL) is the most severe form of these diseases, killing more people Social Sciences and Humanities, Integrated Initiative for Global Health, 360 Huntington than any other parasitic disease except malaria. About 90% of the global burden for VL is Ave., Boston, MA 02115, USA. found in just 7 countries, 4 of which are in Eastern Africa (Sudan, South Sudan, Ethiopia E-mail: [email protected] and Kenya), 2 in Southeast Asia (India, Bangladesh) and Brazil, which carries nearly all of cases in South America. In 2005 the World Health Organization launched a strategy to © 2020 Korean Society of Global Health.
    [Show full text]
  • Identification of Leishmania Donovani Inhibitors from Pathogen Box Compounds of Medicine for Malaria Venture
    bioRxiv preprint doi: https://doi.org/10.1101/716134; this version posted July 26, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Identification of Leishmania donovani inhibitors from pathogen box compounds of Medicine for Malaria Venture Markos Tadele1¶, Solomon M. Abay2¶*, Eyasu Makonnen2,4, Asrat Hailu3 1 Ethiopian institute of agricultural research, Animal health research program, Holetta, Ethiopia 2Department of Pharmacology and clinical pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia 3Department of Microbiology, Immunology and Parasitology, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia 4Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT Africa), College of Health Sciences, Addis Ababa University * Corresponding author Email: [email protected], [email protected] ¶ These authors contributed equally to this work. Author Contributions Conceptualization and design the experiment: MT, SMA, EM, AH Investigation: MT, SMA, AH Data analysis: MT, SMA Funding acquisition and reagents contribution: SMA, AH Supervision: SMA, EM, AH Writing – original draft: MT Writing – review & editing: MT, SMA, EM, AH 1 | P a g e bioRxiv preprint doi: https://doi.org/10.1101/716134; this version posted July 26, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
    [Show full text]
  • Guidelines for Diagnosis, Treatment and Prevention of Visceral Leishmaniasis in South Sudan
    Guidelines for diagnosis, treatment and prevention of visceral leishmaniasis in South Sudan Acromyns DAT Direct agglutination test FDA Freeze – dried antigen IM Intramuscular IV Intravenous KA Kala–azar ME Mercaptoethanol ORS Oral rehydration salt PKDL Post kala–azar dermal leishmaniasis RBC Red blood cells RDT Rapid diagnostic test RR Respiratory rate SSG Sodium stibogluconate TFC Therapeutic feeding centre TOC Test of cure VL Visceral leishmaniasis WBC White blood cells WHO World Health Organization Table of contents Acronyms ...................................................................................................................................... 2 Acknowledgements ....................................................................................................................... 4 Foreword ...................................................................................................................................... 5 1. Introduction ........................................................................................................................... 7 1.1 Background information ............................................................................................... 7 1.2 Lifecycle and transmission patterns ............................................................................. 7 1.3 Human infection and disease ....................................................................................... 8 2. Diagnosis ..............................................................................................................................
    [Show full text]
  • Mucosal Leishmaniasis with Primary Oral Involvement: a Case Series and a Review of the Literature
    Oral Diseases (2014) doi:10.1111/odi.12268 © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd All rights reserved www.wiley.com REVIEW ARTICLE Mucosal leishmaniasis with primary oral involvement: a case series and a review of the literature MD Mignogna1, A Celentano1, S Leuci1, M Cascone1, D Adamo1, E Ruoppo1, G Favia2 1Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II of Naples, Naples; 2Head Oral Surgery Unit, Interdisciplinary Department of Medicine, University of Bari, Bari, Italy OBJECTIVE: To analyze retrospectively a case series of Introduction primary oral leishmaniasis and to review the literature on head–neck primary mucosal leishmaniasis (ML) in Leishmaniasis is a parasitic disease caused by several pro- immunocompetent patients. tozoan species of the genus Leishmania, belonging to the SUBJECTS AND METHODS: A PUBMED search was family Trypanosomatidae. After malaria and African try- ‘ ’ carried out from 1950 to 2013. Clinical records of panosomiasis ( sleeping sickness ), the leishmaniases are patients with primary head–neck mucosal manifesta- the third most important group of vectorborne diseases tions of leishmaniasis were analyzed. In addition, clinical and are ranked ninth in terms of the global burden of dis- records between 2001 and 2012 of patients with pri- ease of all infectious and parasitic diseases (Prabhu et al, mary oral manifestations were collected in two indepen- 1992; Stockdale and Newton, 2013). dent hospitals. The leishmaniases are widely dispersed, with transmis- fi RESULTS: Our multicenter case series revealed seven sion to humans on ve continents, and are endemic in 98 patients with oral leishmaniasis. The most commonly countries.
    [Show full text]
  • Semi-Quantitative, Duplexed Qpcr Assay for the Detection of Leishmania Spp
    Tropical Medicine and Infectious Disease Article Semi-Quantitative, Duplexed qPCR Assay for the Detection of Leishmania spp. Using Bisulphite Conversion Technology Ineka Gow 1,2,*, Douglas Millar 2 , John Ellis 1 , John Melki 2 and Damien Stark 3 1 School of Life Sciences, University of Technology, Sydney, NSW 2007, Australia; [email protected] 2 Genetic Signatures Ltd., Sydney, NSW 2042, Australia; [email protected] (D.M.); [email protected] (J.M.) 3 Microbiology Department, St. Vincent’s Hospital, Sydney, NSW 2010, Australia; [email protected] * Correspondence: [email protected]; +61-466263511 Received: 6 October 2019; Accepted: 28 October 2019; Published: 1 November 2019 Abstract: Leishmaniasis is caused by the flagellated protozoan Leishmania, and is a neglected tropical disease (NTD), as defined by the World Health Organisation (WHO). Bisulphite conversion technology converts all genomic material to a simplified form during the lysis step of the nucleic acid extraction process, and increases the efficiency of multiplex quantitative polymerase chain reaction (qPCR) reactions. Through utilization of qPCR real-time probes, in conjunction with bisulphite conversion, a new duplex assay targeting the 18S rDNA gene region was designed to detect all Leishmania species. The assay was validated against previously extracted DNA, from seven quantitated DNA and cell standards for pan-Leishmania analytical sensitivity data, and 67 cutaneous clinical samples for cutaneous clinical sensitivity data. Specificity was evaluated by testing 76 negative clinical samples and 43 bacterial, viral, protozoan and fungal species. The assay was also trialed in a side-by-side experiment against a conventional PCR (cPCR), based on the Internal transcribed spacer region 1 (ITS1 region).
    [Show full text]